特别关注｜PD-1/PD-L1在肝细胞癌治疗中的应用(16)

[28]QIN SK, REN ZG, FENG YS, et al. OP02-03 efficacy and safety of atezolizumab bevacizumab vs sorafenib in Chinese patients with unresectable HCC in the phase Ⅲ IMbrave150 study.[EB/OL]. (2020-02-06)[2020-06-20]. https://easl.eu/livercancersummit2020/wp-content/uploads/2020/01/Liver-Cancer-Summit-2020-Abstract-book.pdf.
[29]YAU T, KANG YK, KIM TY, et al. Nivolumab (NIVO) ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040[J]. J Clin Oncol, 2019, 37(15 Suppl): 4012.
[30]HE AR, YAU T, HSU C, et al. Nivolumab (NIVO) ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040[J]. J Clin Oncol, 2020, 38(4 Suppl): 512.
[31]KELLEY RK, SANGRO B, HARRIS WP, et al. Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. J Clin Oncol, 2020, 38(15 Suppl): 4508.